NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Lite Strategy, Inc. LITS
18 fiscal years on record · USD · FY2024 reported · SEC filings only
Growth
—
Revenue, FY2024 · full 18-year series below
Revenue $M
Net income $M
FY2024 · Revenue 0.0 · Net income -15.9
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2023 · Operating 22.3% · Net 27.2%
ROE
FY2024 · ROE -63.8%
Each USD of equity lost 64 cents this year.
The 18-year record
18 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · |
| Operating income $B | −0.0 | 0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · |
| EBITDA $B | −0.0 | 0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · |
| Net income $B | −0.0 | 0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | 0.0 | −0.0 | · | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | −0.0 | · | · | · |
| EPS, diluted $ | −2.39 | 2.67 | −4.78 | −9.99 | −0.60 | −0.52 | −0.75 | −0.97 | 0.07 | −0.61 | −1.16 | −1.35 | −1.10 | −3.35 | −0.89 | · | · | · |
| Dividend / sh $ | · | 1.75 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | −0 | 66 | −0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −63.8 | 61.7 | −83.1 | −106.0 | −64.8 | −75.5 | −34.2 | −79.1 | 5.8 | −41.1 | −62.3 | −67.8 | −56.7 | −235.4 | −147.8 | −69.9 | −70.4 | −75.1 |
| Shares out B | 0.01 | 0.01 | 0.01 | 0.01 | 0.11 | 0.11 | 0.07 | 0.07 | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | 0.00 | 0.01 | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 63 reconciliationsAUDITED
Reconciled in 18 of 19 fiscal years. 26 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2007